Pain
Conditions
Brief summary
The purpose of the study is primarily to determine the safety and toleration and pharmacokinetics of PF-05089771 following escalating multiple doses lasting for 14 days.
Interventions
DRUGPF-05089771
PF-05089771 will be dosed as a suspension twice daily (BID)
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male subjects or female subjects of non-child bearing potential between the ages of 18 and 55 years, inclusive. * elderly cohort : healthy male and/or female subjects of 65 and 74 years, * cohort 3: subjects with osteoarthritis of the knee: Male or female subjects not of child bearing potential between the ages of 18 and 75 years inclusive at the time of entering the study.
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug screen. * History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening. * Treatment with an investigational drug within 60 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication. * 12-lead ECG demonstrating QTc \>450 msec or a QRS interval \>120 msec at Screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the subject's eligibility. * Use of prescription or non-prescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. * As an exception, acetaminophen/paracetamol may be used at doses of ≤1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor. * Blood donation of approximately 1 pint (500 mL) or more within 56 days prior to dosing. * History of sensitivity to heparin or heparin-induced thrombocytopenia. * Unwilling or unable to comply with the Lifestyle guidelines described in this protocol. * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. for cohort 3: Evidence of relapse or recurrence of clinically significant endocrine, metabolic, pulmonary, hepatic, osteo-mio-artricular, gastrointestinal, cardiovascular, renal, , psychiatric or neurological disease, or neurological disease less than 28 days prior to screening. Symptomatic OA of the hip ipsilateral to index knee which the patient considers more painful than the knee. History of diseases other than OA that may involve the index knee in the last 12 months prior to screening, including but not limited to: inflammatory joint diseases (i.e rehumatoid arthritis and gout), calcium crystal diseases, bursitis, tendinitis, tumors and cysts, ligament injuries, bone fractures, post-infective pathologies; widespread chronic pain conditions (ie, fibromyalgia) and neuropathic disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events as a measure of safety and tolerability of PF-05089771 | Days 1-16 |
| Maximum concentration (Cmax) for PF-05089771 in plasma (measured in ng/mL) | Days 1, 4 and 14 |
| Tmax = Time of maximum concentration of PF-05089771 in plasma (hr) | Days 1, 6 and 14 |
| AUCtau= Area under the curve from the time of dosing to the next dose (ng.hr/mL) | Days 1, 6 and 14 |
| Elimination half life (hr) = rate of elimination of PF-05089771 after the final dose | day 14 PK samples collected only for 48 hours |
Secondary
| Measure | Time frame |
|---|---|
| AUCinf = Area under the curve from the time of dosing extrapolated to infinity (ng.hr/mL) | Days 14, over 48 hours of PK samples collection |
| Daily pain following self paced walk. | Days 14, every day over 24 hours |
| Daily pain score throughout the treatment period using an 11-point Numeric Rating Scale (NRS). | Days 14, every day over 24 hours |
| Daily time to ascend and descend stairs. | Days 14, every day over 24 hours |
| Daily pain following stair climbing and descending | Days 14, every day over 24 hours |
| Daily time for self paced walk | Days 14, every day over 24 hours |
Countries
Belgium
Outcome results
None listed